Hamill John P. 4
4 · Aprea Therapeutics, Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Aprea CFO John Hamill Acquires 30,978 Pre-Funded Warrants
What Happened
- John P. Hamill, Sr. VP, Chief Financial Officer and Principal Financial & Accounting Officer of Aprea Therapeutics (APRE), participated in a private placement that closed March 31, 2026. He acquired 30,978 pre-funded warrants and 30,978 accompanying common warrants. The reported cost for the pre-funded warrants was $0.81 each, totaling $24,999 (reported as a derivative acquisition). The filing lists the transaction as a purchase (code P), which is a net acquisition of potential future shares rather than an outright purchase of common stock.
Key Details
- Transaction date: March 31, 2026; Form 4 filed April 1, 2026 (timely).
- Reported amount: 30,978 pre-funded warrants and 30,978 common warrants.
- Reported price/value: Pre-funded warrants at $0.81 each; total reported value $24,999.
- Shares owned after transaction: Not specified in the provided summary (not disclosed here).
- Footnotes of note:
- The pre-funded warrants were issued in a private placement under a securities purchase agreement and are immediately exercisable.
- Exercise is subject to a Beneficial Ownership Limitation: exercise cannot cause the holder (with affiliates) to exceed 4.99% of outstanding common stock or 9.99% of combined voting power.
- Common warrants are immediately exercisable subject to the same ownership limit and expire on December 31, 2029 (or 30 days after any pre-funded warrant exercise, pro rata).
- Transaction code: P = Purchase (derivative securities).
Context
- A pre-funded warrant is effectively a nearly-paid-for right to receive common stock after paying a nominal exercise price; it’s often used so an investor can buy equity without immediately increasing a company’s public float above certain ownership thresholds.
- This is an acquisition of derivative securities (warrants), not an outright purchase of common shares. Such purchases show the insider has the option to acquire shares later but do not immediately change public share count unless exercised.
- Purchases by officers are often considered more informative than sales, but they do not by themselves indicate future company performance.
Insider Transaction Report
Form 4
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Transactions
- Purchase
Pre-Funded Warrant
[F1][F2]2026-03-31$0.81/sh+30,978$24,999→ 30,978 totalExercise: $0.00From: 2026-03-31→ Common Stock (30,978 underlying) - Purchase
Common Warrant
[F1][F3]2026-03-31+30,978→ 30,978 totalExercise: $0.68From: 2026-03-31→ Common Stock (30,978 underlying)
Footnotes (3)
- [F1]On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 30,978 Shares.
- [F2]The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation")
- [F3]The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise.
Signature
/s/ John Hamill|2026-04-01